Green M D, Sherman P, Zalcberg J
Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Invest New Drugs. 1992 Apr;10(1):31-4. doi: 10.1007/BF01275477.
Fifteen patients with advanced head and neck cancer not curable with radiation or surgery were entered into a phase II study of 10-EdAM. None of the patients had received prior chemotherapy. 10-EdAM was administered intravenously at a dose of 80 mg/m2 each week. Four patients were not eligible for evaluation. Two died before completing four cycles of chemotherapy, one refused further treatment and one developed hepatic toxicity resulting in withdrawal. Of the remaining patients, three had a partial response. The major toxicities were leukopenia and mucositis.
15例无法通过放疗或手术治愈的晚期头颈癌患者进入了10-EdAM的II期研究。所有患者此前均未接受过化疗。10-EdAM以每周80 mg/m²的剂量静脉给药。4例患者不符合评估条件。2例在完成4个化疗周期前死亡，1例拒绝进一步治疗，1例出现肝毒性而退出研究。其余患者中，3例有部分缓解。主要毒性为白细胞减少和粘膜炎。
